These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 24375987)

  • 1. Retrospective evaluation of antithrombin III supplementation in neonates and infants receiving enoxaparin for treatment of thrombosis.
    Corder A; Held K; Oschman A
    Pediatr Blood Cancer; 2014 Jun; 61(6):1063-7. PubMed ID: 24375987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enoxaparin use in the neonatal intensive care unit: experience over 8 years.
    Malowany JI; Knoppert DC; Chan AK; Pepelassis D; Lee DS
    Pharmacotherapy; 2007 Sep; 27(9):1263-71. PubMed ID: 17723080
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
    Michaels LA; Gurian M; Hegyi T; Drachtman RA
    Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do neonates, infants and young children need a higher dose of enoxaparin in the cardiac intensive care unit?
    Sanchez de Toledo J; Gunawardena S; Munoz R; Orr R; Berry D; Sonderman S; Krallman S; Shiderly D; Wang L; Wearden P; Morell VO; Chrysostomou C
    Cardiol Young; 2010 Apr; 20(2):138-43. PubMed ID: 20199704
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fluctuations of anti-Xa concentrations during maintenance enoxaparin therapy for neonatal thrombosis.
    Lulic-Botica M; Rajpurkar M; Sabo C; Tutag-Lehr V; Natarajan G
    Acta Paediatr; 2012 Apr; 101(4):e147-50. PubMed ID: 22211705
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
    Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
    Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel uses of insulin syringes to reduce dosing errors: a retrospective chart review of enoxaparin whole milligram dosing.
    Bauman ME; Black KL; Bauman ML; Belletrutti M; Bajzar L; Massicotte MP
    Thromb Res; 2009 Apr; 123(6):845-7. PubMed ID: 19038418
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anti-Xa activity relates to survival and efficacy in unselected acute coronary syndrome patients treated with enoxaparin.
    Montalescot G; Collet JP; Tanguy ML; Ankri A; Payot L; Dumaine R; Choussat R; Beygui F; Gallois V; Thomas D
    Circulation; 2004 Jul; 110(4):392-8. PubMed ID: 15249498
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Non-therapeutic anti-Xa levels in medical patients receiving anticoagulant therapy with enoxaparin.
    Ramos-Esquivel A; Salazar-Sánchez L
    Thromb Res; 2013 Oct; 132(4):433-6. PubMed ID: 24050826
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of anti-Xa levels in obese and non-obese pediatric patients receiving treatment doses of enoxaparin.
    Richard AA; Kim S; Moffett BS; Bomgaars L; Mahoney D; Yee DL
    J Pediatr; 2013 Feb; 162(2):293-6. PubMed ID: 22959138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
    Hammerstingl C; Omran H; Tripp C; Poetzsch B
    Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing and monitoring of enoxaparin therapy in children: experience in a tertiary care hospital.
    Andrade-Campos MM; Montes-Limón AE; Fernandez-Mosteirin N; Salvador-Osuna C; Torres M; Lucia-Cuesta JF; Rubio-Felix D
    Blood Coagul Fibrinolysis; 2013 Mar; 24(2):194-8. PubMed ID: 23358201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Enoxaparin Dosing as a Risk Factor for Bleeding in Lung Transplant Recipients.
    Sofjan AK; Iuppa JA; Bain KB; Deal EN; Witt CA; Hachem RR; Yusen RD
    Ann Pharmacother; 2016 Oct; 50(10):824-31. PubMed ID: 27363845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of enoxaparin dosing requirements in infants and children. Better dosing to achieve therapeutic levels.
    Bauman ME; Belletrutti MJ; Bajzar L; Black KL; Kuhle S; Bauman ML; Patricia Massicotte M
    Thromb Haemost; 2009 Jan; 101(1):86-92. PubMed ID: 19132193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Retrospective evaluation of enoxaparin dosing in patients 48 weeks' postmenstrual age or younger in a neonatal intensive care unit.
    Hicks JK; Shelton CM; Sahni JK; Christensen ML
    Ann Pharmacother; 2012; 46(7-8):943-51. PubMed ID: 22828970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The risk of bleeding associated with low molecular weight heparin in patients with renal failure].
    Lai S; Barbano B; Cianci R; Gigante A; Di Donato D; Asllanaj B; Dimko M; Mariotti A; Morabito S; Pugliese F
    G Ital Nefrol; 2010; 27(6):649-54. PubMed ID: 21132647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors influencing enoxaparin anti-Xa activity in surgical critically ill patients.
    Vincent PD; Albert M; Champagne MC; Zikos T; Boulanger I; Blais L; Williamson DR
    J Crit Care; 2011 Aug; 26(4):347-51. PubMed ID: 21454037
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early ambulation and variability in anticoagulation during elective coronary stenting with a single intravenous bolus of low-dose, low-molecular weight heparin enoxaparin.
    Zalc S; Lemos PA; Esteves A; Ribeiro EE; Horta P; Nicolau JC; Ramires JA; Cohen M; Martinez EE
    J Invasive Cardiol; 2006 Feb; 18(2):45-8. PubMed ID: 16446514
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alternative dosing of prophylactic enoxaparin in the trauma patient: is more the answer?
    Kopelman TR; O'Neill PJ; Pieri PG; Salomone JP; Hall ST; Quan A; Wells JR; Pressman MS
    Am J Surg; 2013 Dec; 206(6):911-5; discussion 915-6. PubMed ID: 24296098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Outcomes following routine antithrombin III replacement during neonatal extracorporeal membrane oxygenation.
    Stansfield BK; Wise L; Ham PB; Patel P; Parman M; Jin C; Mathur S; Harshfield G; Bhatia J
    J Pediatr Surg; 2017 Apr; 52(4):609-613. PubMed ID: 27847121
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.